Karnataka FDA notice puts Peptide OS and India’s grey-market peptide trade under scrutiny
Karnataka’s FDA halted a Bengaluru event and sought licences, batch records, import invoices and clinical evidence from Peptide OS—spotlighting compliance risks for D2C wellness sellers and B2B marketplaces offering peptides.
What happened
Karnataka FDA halted a Bengaluru peptide event and issued Peptide OS a notice seeking licences, batch details, import invoices and clinical evidence,
Key facts
- 29 August
- 50 guests
- two-year-old
- $328 million
- 2025
- Section 22
Why this matters
Treat peptide targets and partnerships as enhanced-diligence cases, requiring verified product classification, regulator-ready documentation, supplier controls and indemnities around claims and import compliance.
What to watch
- Whether Karnataka FDA issues a formal show-cause notice, seizure order, product ban, prosecution or only document-compliance directions.
- Requests for central CDSCO involvement, import-license verification, customs action or coordinated inspections in other Indian states.
- Peptide OS disclosures on product licences, batch testing, importer-of-record status, clinical evidence and event permissions.
- Major marketplaces updating prohibited-product rules or delisting peptide, injectable or research-use-only listings.
- Enforcement against influencer promotions, wellness events, clinics or telehealth providers making peptide-related claims.
- Reports of adverse events, counterfeit products, cold-chain failures or unapproved injectable formulations.
- Audit all peptide-related SKUs, supplier agreements, import documents, batch records, storage conditions and product classifications.
- Immediately remove or revise disease-treatment, weight-loss, anti-aging, hormone and performance claims that lack substantiation or required approvals.
- Require marketplace sellers to submit licences, invoices, certificates of analysis, manufacturing details and clinical-evidence files before listing or relisting.
- Create a restricted-products policy covering peptides, injectable wellness products, research chemicals and prescription-adjacent compounds.
- Shift marketing spend toward legally lower-risk wellness categories while compliance reviews are underway.
- Prepare customer-service, recall and adverse-event escalation protocols in case regulators request product traceability or consumer disclosures.